AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Elekta

Annual Report May 28, 2025

2906_10-k_2025-05-28_de9a8583-bd73-47f7-b991-0c656bc78f3d.pdf

Annual Report

Open in Viewer

Opens in native device viewer

Year-end report

May–April 2024/25

Earnings momentum

Fourth quarter

  • In constant exchange rates, net sales increased by 6 percent mainly driven by Europe and APAC. Reported sales increased by 3 percent amounting to SEK 5,156 M (5,023).
  • Book-to-bill ratio of 1.12 (1.28) supported by continued strong order growth for Elekta Evo.
  • Improved adjusted gross margin of 40.3 percent (36.6) supported by volumes, price increases and product mix.
  • Non-cash impairment amounting to SEK 1,064 M was booked during the quarter due to discontinued R&D projects.
  • Adjusted EBIT amounted to SEK 843 M (651), corresponding to margin of 16.3 percent (13.0).
  • Delivered on Cost-reduction Initiative amounting to SEK 279 M in annual run rate savings.
  • Net income was SEK -381 M (414) impacted by the non-cash impairment. EPS before and after dilution was SEK -1.01 (1.08).
  • Strong cash flow of SEK 1,248 M (872) after continuous investments.
  • Despite present market conditions and current political and macro-economic visibility, net sales are expected to grow YoY.
  • Gustaf Salford left the position as President and CEO March 6 external recruitment process proceeds as planned.

Full year

  • In constant exchange rates, net sales increased by 1 percent mainly driven by Europe and APAC. Reported sales decreased by 1 percent amounting to SEK 18,016 M (18,119).
  • Book-to-bill ratio of 1.09 (1.09) with positive impact from product launches in Europe and recovery in China.
  • Improved adjusted gross margin of 37.8 percent (37.5) supported by price increases and product mix.
  • Adjusted EBIT amounted to SEK 2,097 M (2,145), corresponding to a margin of 11.6 percent (11.8).
  • Net income was SEK 240 M (1,302) impacted by the non-cash impairment. EPS before and after dilution was SEK 0.62 (3.41).
  • Improved cash flow of SEK 1,056 M (815) after continuous investments.
  • The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments) for FY2024/25.
Q4 Full year
SEK M 2024/25 2023/24 Δ 2024/25 2023/24 Δ
Book-to-bill 1.12 1.28 -12% 1.09 1.09 1%
Net sales 5,156 5,023 3% 18,016 18,119 -1%
Net sales in constant exchange rates 6% 1 1%
Adjusted gross margin 2 40.3% 36.6% 3.7 ppts 37.8% 37.5% 0.3 ppts
Adjusted EBITDA 3 1,165 956 22% 3,396 3,287 3%
Adjusted EBITDA margin 3 22.6% 19.0% 3.6 ppts 18.8% 18.1% 0.7 ppts
Adjusted EBIT 4 843 651 29% 2,097 2,145 -2%
Adjusted EBIT margin 4 16.3% 13.0% 3.4 ppts 11.6% 11.8% -0.2 ppts
Gross margin 39.8% 36.4% 3.4 ppts 37.4% 37.4% 0 ppts
EBITDA 1,189 930 28% 3,283 3,189 3%
EBITDA margin 23.1% 18.5% 4.5 ppts 18.2% 17.6% 0.6 ppts
EBIT -197 617 -132% 890 2,039 -56%
EBIT margin -3.8% 12.3% -16.1 ppts 4.9% 11.3% -6.3 ppts
Net income -381 414 -192% 240 1,302 -82%
Cash flow
after continuous investments
1,248 872 376 1,056 815 241
Adjusted earnings per share before/after dilution, SEK 5 1.11 / 1.11 1.15 / 1.15 -4% 3.08 / 3.08 3.62 / 3.62 -15%
Earnings per share before/after dilution, SEK -1.01 / -1.01 1.08 / 1.08 -193% 0.62 / 0.62 3.41 / 3.41 -82%
1
Compared to last fiscal year based on constant exchange rates.
2
Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative and the R&D impairment cost., see page 28.
3
Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative and the R&D impairment cost, see page 28.
4
Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability and the R&D impairment cost, see page 29.
5
Adjusted earnings per share = Net income excluding items affecting comparability, attributable to Parent Company shareholders, in relation to the weighted average number of shares (excluding treasury shares), see page 30

Strong growth in software and price increases contributed to the best Q4 gross margin in five years. Our latest linear accelerator, Elekta Evo, and the new additions to our software suite, Elekta ONE, continued to generate order and sales growth. A non-cash impairment amounting to SEK 1,064 M was booked in Q4 due to discontinued R&D projects.

Earnings momentum

In spite of a decline in orders in Q4, our book-to-bill ratio stands strong at 1.12 for Q4 and at 1.09 for the full year of 2024/25, mainly driven by our latest linear accelerator, Elekta Evo, and the new additions to our software suite, Elekta ONE. Net sales at constant exchange rates increased by 6 percent in Q4 and 1 percent for the full year, in line with our guidance.

I am pleased that we ended the year with a gross margin of 40.3 percent (36.6). This was the best Q4 gross margin in five years, an important step in our ambition to return to pre-pandemic levels. The EBIT margin ended at 16.3 percent (13.0) in Q4. Double-digit growth in our software business, price increases as well as product launches and a solid development for our specialty products contributed to the strong earnings momentum. Operating cash flow after continuous investments improved by SEK 241 M to SEK 1,056 M for the full year. The Board proposes a dividend of SEK 2.40 (2.40) per share to the AGM, underlining Elekta's strong financial position.

Actions taken during Q4

During the quarter we completed a review of Elekta's R&D assets on the balance sheet, which has resulted in a non-cash impairment amounting to SEK 1,064 M due to discontinued R&D projects. The impairment is mainly a consequence of a change of scope within software partly driven by moving from an internally developed cloud ware solution to an external supplier's platform.

In consultation with the U.S. Food and Drug Administration (FDA), we changed our regulatory submission strategy in mid-May for Elekta Evo to better align with the FDA´s approval process with greater focus on cybersecurity. We expect that the impact of this delay on the overall project launch will be limited. Meanwhile,

Elekta Evo and our software suite Elekta ONE are fully operational, currently in clinical use, and have received outstanding feedback from healthcare providers across Europe.

Customer wins

During the quarter, we delivered on several important commercial wins such as Elekta Evo, our software suite Elekta ONE, and a comprehensive deal comprising some of our most advanced solutions to the University of Texas Southwestern.

At the annual ESTRO congress in Vienna, there was great customer interest in our online adaptive treatment capabilities on Elekta Evo with Elekta ONE Planning, as well as Elekta Unity's superiority in preserving healthy tissue, not least manifested by the ERECT trial in Utrecht showing astounding results in maintaining erectile function for prostate cancer patients.

Guidance

Despite present market conditions and current political and macro-economic visibility, net sales are expected to grow year-over-year. We expect Gross and EBIT margins to expand, driven by price increases, product launches and volumes, resulting in a stepwise improvement towards our midterm targets to move the gross margin to prepandemic levels and an EBIT margin of 14% and higher. For Q1 2025/26, we expect normal seasonal development with low sales volumes as well as negative FX-effects.

Jonas Bolander President and CEO

40.3% Q4 adj. gross margin

"The best Q4 gross margin in five years."

Financial highlights

Net sales

  • 6 percent increase in constant exchange rates driven by Europe and APAC
  • Strong momentum in Europe supported by new product launches
  • The book-to-bill ratio was 1.12 (1.28) in the fourth quarter

Based on constant exchange rates, Elekta's net sales increased by 6 percent in the fourth quarter. The development was mainly driven by strong performance in Europe and most markets in APAC while U.S. net sales continued to be weak. Reported net sales increased by 3 percent amounting to SEK 5,156 M (5,023).

Sales in EMEA increased by 16 percent in constant exchange rates compared to last year, driven by the continued strong momentum in Europe supported by new product launches. APAC sales grew by 5 percent in constant exchange rates with good performance across most markets. The Chinese market continued to remain soft, however improvements were seen during the quarter resulting in a limited sales decline of 1 percent compared to last year. In the Americas, the development was similar to the third quarter of fiscal year 2024/25 where growth in South America was fully offset by a weak development in

the U.S. mainly as a consequence of customers awaiting the Elekta Evo clearance.

Solutions and Service increased sales by 7 percent and 4 percent respectively in constant exchange rates supported by growth in software.

Book-to-bill development

The book-to-bill ratio was 1.12 (1.28) in the fourth quarter and 1.09 (1.09) for the full year 2024/25. Gross order intake in the fourth quarter amounted to SEK 5,792 M (6,436), a decrease of 10 percent in SEK and 7 percent based on constant exchange rates.

For more information about the book-to-bill ratio, see page 30.

Sales per region

Q4
Full year
SEK M 2024/25 2023/24 1
Δ
Δ 2024/25 2023/24 1
Δ
Δ
Americas 1,371 1,526 -6% -10% 5,183 5,436 -2% -5%
EMEA 2,014 1,769 16% 14% 6,580 6,550 1% 0%
APAC 1,771 1,728 5% 2% 6,253 6,134 4% 2%
Group 5,156 5,023 6% 3% 18,016 18,119 1% -1%

Sales per product type

Q4 Full year
SEK M 2024/25 2023/24 1
Δ
Δ 2024/25 2023/24 1
Δ
Δ
Solutions 3,186 3,060 7% 4% 10,232 10,633 -2% -4%
Service 1,970 1,963 4% 0% 7,784 7,487 6% 4%
Group 5,156 5,023 6% 3% 18,016 18,119 1% -1%

1 Based on constant exchange rates.

FINANCIAL HIGHLIGHTS

Earnings

  • Improved adjusted gross margin supported by volumes, price increases and product mix
  • Higher amortization costs following recent product launches
  • EBIT negatively impacted by a non-cash impairment of SEK 1,064 M

Gross income development

In the fourth quarter, the adjusted gross income was SEK 2,075 M (1,837), representing an adjusted gross margin of 40.3 percent (36.6). The increase was supported by higher volumes, price improvements, and a favorable product mix with a larger share of high-margin devices as well as strong software growth. Changes in foreign exchange rates had a negative impact. Reported gross income amounted to SEK 2,053 M (1,829), representing a margin of 39.8 percent (36.4).

Impact of impairment

The fourth quarter results include a non-cash impairment amounting to SEK 1,064 M due to discontinued R&D projects, representing approximately 8% of total intangible and tangible assets on the balance sheet. Elekta is regularly performing asset impairment reviews in accordance with IFRS requirements. Following a change of direction of the product development roadmap during the quarter, some projects will not be continued or will not deliver according to the original business plan.

The impairment is reported as an item affecting comparability (IAC) and mainly includes items presented as R&D expenses. For more information, see note 5 and the presentation of IAC on page 27. Elekta expects that the impact from the impairment will amount to SEK 100 M in yearly lower amortization.

EBIT development

Adjusted EBIT came in at SEK 843 M (651), representing a margin of 16.3 percent (13.0). The higher adjusted EBIT margin derives mainly from the gross margin partially offset by higher amortization costs. Furthermore, changes in foreign exchange rates had a negative impact.

Reported EBIT, including the impairment, amounted to SEK -197 M (617), representing a margin of -3.8 percent (12.3). IAC in the fourth quarter amounted to SEK 1,040 M, of which SEK 1,064 M relates to the impairment partially offset by positive items mainly related to the impairment of SEK 24 M. IAC amounting to SEK 22 M (7) impacted the gross margin in Q4.

Operating expenses, excluding IAC and based on constant exchange rates, increased by 6 percent during the fourth quarter. The increase was mainly driven by higher amortization of intangible assets following recent product launches.

Net income development

Net financial items increased slightly to SEK -109 M (-88), explained by higher interest expenses and a negative non-cash effect related to revaluation of the operations in Turkey with regards to its hyperinflation. Taxes amounted to SEK 74 M (115), representing a tax rate of 24 percent (22). Net income, impacted by the impairment, amounted to SEK -381 M (414) and earnings per share to SEK -1.01 (1.08) before and after dilution.

Q4 Full year
SEK M 2024/25 2023/24 Δ 2024/25 2023/24 Δ
Net sales 5,156 5,023 3% 18,016 18,119 -1%
Net sales in constant currency 6% 1%
Adjusted gross income 2,075 1,837 13% 6,810 6,803 0%
Adjusted gross margin 40.3% 36.6% 3.7 ppts 37.8% 37.5% 0.3 ppts
Adjusted EBIT 843 651 29% 2,097 2,145 -2%
Adjusted EBIT-margin 16.3% 13.0% 3.4 ppts 11.6% 11.8% -0.2 ppts
EBIT -197 617 -132% 890 2,039 -56%
EBIT-margin -3.8% 12.3% -16.1 ppts 4.9% 11.3% -6.3 ppts
Net income -381 414 -192% 240 1,302 -82%
Earnings per share -1.01 1.08 -193% 0.62 3.41 -82%

FINANCIAL HIGHLIGHTS

Earnings

Cost-reduction Initiative

As part of Elekta's ongoing efforts to improve cost efficiency, the company delivered on its previously announced Cost-reduction Initiative. On April 30, 2025, cost savings amounted to SEK 279 M in annual run rate savings with SEK 145 M impacting fiscal year 2024/25. The target was SEK 250 M in annual run rate savings at an estimated implementation cost of SEK 250 M. The costs amounted to SEK 189 M and are reported as items affecting comparability, see page 27.

Employees

The average number of employees on April 30, 2025, was 4,536 (4,607).

Shares

Total number of registered shares on April 30, 2025, was 383,568,409, of which 14,980,769 were A-shares and 368,587,640 B-shares. On April 30, 2025, 1,485,289 shares were treasury shares held by Elekta. Earnings per share was SEK -1.01 (1.08) before and after dilution.

Cash flow and financial position

  • Strong cash flow of SEK 1,248 M after continuous investments
  • Full year 2024/25 net working capital as a percentage of net sales at -9 percent
  • Proposed dividend of SEK 2.40 per share

Cash flow

Cash flow after continuous investments amounted to SEK 1,248 M (872), an increase of SEK 376 M compared to last year. The increase is mainly driven by higher EBITDA and lower investments. Full year 2024/25 net working capital as a percentage of net sales was -9 percent (-10).

Investments in intangible assets amounted to SEK 291 M (378) and were mainly related to R&D investments in new product solutions and software. Investments in tangible assets decreased to SEK 28 M (67). Cash conversion in the fourth quarter was 132 percent (142).

Cash flow (extract)

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
EBITDA 1,189 930 3,283 3,189
Change in w
orking capital
364 441 -203 -220
Financial net -109 -88 -400 -371
Paid tax -15 -27 -311 -431
Other 139 63 258 295
Cash flow from operating
activities
1,568 1,317 2,626 2,461
Continuous investments -320 -445 -1,570 -1,645
Cash flow after continuous
investments
1,248 872 1,056 815
Operational cash conversion 132% 142% 80% 77%

Financial position

Cash and cash equivalents and short-term investments amounted to SEK 2,955 M (2,779). The increase compared to last year is driven by higher earnings and a positive net intake of cash between the bond issued on October 1, 2024, amounting to SEK 1,500 M and the repayment of a bond amounting to SEK 1,000 M on March 13, 2025. Interest-bearing liabilities, excluding lease liabilities, amounted to SEK 6,373 M (5,929).

Net debt increased to SEK 3,477 M (3,150) as a result of continuous investments in R&D innovation and acquisitions. Net debt in relation to EBITDA was 1.06 (0.99). The average maturity of interest-bearing liabilities was 3.3 years.

Dividend

The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 M.

Net debt

Apr 30 Apr 30
SEK M 2025 2024
Long-term interest-bearing liabilities 6,195 4,807
Short-term interest-bearing liabilities 178 1,122
Derivatives, net 60 -
Cash and cash equivalents and short-term
investments
-2,955 -2,779
Net debt 3,477 3,150
Long-term lease liabilities 961 1,095
Short-term lease liabilities 233 224
Net debt including lease liabilities 4,671 4,469
Net debt/EBITDA ratio 1 1.06 0.99

1 EBITDA 12 months rolling

Other information

Risk and uncertainties

Elekta's presence in many geographical markets exposes the Group to political and economic risks on a global scale and/or in individual countries. For more details, please see the Annual Report 2023/24, page 25. Recent updates to these risk factors and uncertainties, which Elekta considers to be of short-term relevance, include but are not limited to the following risks outlined below:

Geopolitical tensions, including tariffs, restrictions, protectionism and the expansion of sanctions may impact Elekta's local partnering, manufacturing and sales in certain markets, potentially exposing us to conflicting trade compliance sanctions.

Forward looking statements

This is information such that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the below mentioned contact persons at 07:30 CEST on May 28, 2025. This report includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forwardlooking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Some of these risks and uncertainties are described further in the section "Risk and uncertainties". Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations.

Parent company

During the year, operating income and expenses have increased due to higher support in relation to expenses. Operating income increased due to higher finance net

that was positively affected by increased dividends from subsidiaries partly offset by an impairment of shares in subsidiaries of SEK 404 M.

All external loans are considered long-term in the fourth quarter of fiscal year 2024/25 in comparison to last year when SEK 1,000 M was short-term.

Significant events

Gustaf Salford to leave position as President and CEO of Elekta as of March 6

Elekta announced that Gustaf Salford, President and CEO, and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6. Jonas Bolander, Executive Vice President, General Counsel & Head of Group Functions, will assume the CEO position until a new CEO is in office.

Elekta and Azra AI announce partnership to enhance cancer registry operations with AI-powered automation Elekta announced that it has partnered with Azra AI, the industry's only end-to-end oncology workflow automation platform, to enhance cancer registry operations through automation and AI-powered data management.

Significant events after the quarter

Clinical trial shows more precise radiotherapy using Elekta Unity MR-Linac preserves sexual function in men with prostate cancer

ERECT trial used MR-guidance to spare nerves and blood vessels essential for achieving and maintaining an erection.

Shareholder information

Conference call Q4

Elekta will host a web conference at 10:00-11:00 CEST on May 28 with President and CEO Jonas Bolander, and CFO Tobias Hägglöv. To take part of the presentation please dial the numbers or watch via the web link below.

Sweden: +46 (0) 8 5051 0031 UK: +44 (0) 207 107 06 13 USA: +1 (1) 631 570 56 13

For further information, please contact:

Tobias Hägglöv CFO +46 76 107 4799 [email protected]

Peter Nyquist VP, Head of Investor Relations +46 70 575 2906 [email protected]

Financial calendar

Annual Report 2024/25 Jul 4, 2025 Interim report, Q1, May-Jul 2025/26 Aug 28, 2025 Annual General Meeting 2025 Sep 4, 2025 Interim report, Q2, May-Oct 2025/26 Nov 26, 2025 Interim report, Q3, May-Jan 2025/26 Mar 5, 2026 Interim report, Q4, May-Apr 2025/26 May 28, 2026

Web link

>

Stockholm May 28, 2025

Jonas Bolander President and CEO

This report has not been reviewed by the Company's auditors.

Consolidated income statement – condensed

Q4 Full year
SEK M
Note
2024/25 2023/24 2024/25 2023/24
Net sales
3
5,156 5,023 18,016 18,119
Cost of products sold -3,102 -3,194 -11,270 -11,342
Gross income 2,053 1,829 6,746 6,777
Selling expenses -411 -411 -1,650 -1,641
Administrative expenses -363 -366 -1,412 -1,370
R&D expenses -1,376 -354 -2,676 -1,404
Other operating income and expenses -56 -29 -108 -102
Exchange rate differences -45 -51 -
9
-221
Operating income (EBIT) -197 617 890 2,039
Financial items, net -109 -88 -400 -371
Income after financial items -307 529 490 1,668
Income tax -74 -115 -250 -365
Net income for the period
2
-381 414 240 1,302
Net income for the period attributable to:
Parent Company shareholders -386 415 237 1302
Non-controlling interests 5 0 4 0
Earnings per share
Before dilution, SEK -1.01 1.08 0.62 3.41
After dilution, SEK -1.01 1.08 0.62 3.41

Consolidated statement of comprehensive income

SEK M
2024/25
2023/24
2024/25
2023/24
Net income for the period
-381
414
240
1,302
Other comprehensive income:
Items that w
ill not be reclassified to the income statement:
Remeasurements of defined benefit pension plans
1
-
8
1
-
8
Tax
-
3
1
-
3
1
Total items that will not be reclassified to the income statement
-
2
-
7
-
2
-
7
Items that subsequently may be reclassified to the income statement:
Revaluation of cash flow
hedges
169
-49
94
81
Translation differences from foreign operations
-1,281
609
-1,385
583
Tax
-35
10
-19
-17
Total items that subsequently may be reclassified to the income statement
-1,147
570
-1,311
648
Other comprehensive income for the period
-1,149
564
-1,312
641
Total comprehensive income for the period
-1,530
978
-1,072
1,943
Comprehensive income attributable to:
Parent Company shareholders
-1,529
978
-1,072
1,942
Non-controlling interests
-
1
0
0
1
Q4 Full year

Consolidated balance sheet statement – condensed

Apr 30
SEK M
Note
2025 2024
Non-current assets
Intangible assets 11,917 13,336
Right-of-use assets
5
1,006 1,164
Tangible assets 901 1,062
Financial assets 895 1,092
Deferred tax assets 841 801
Total non-current assets 15,560 17,455
Current assets
Inventories 2,756 3,259
Accounts receivable 3,625 3,877
Accrued income 2,261 2,050
Other current receivables 1,820 1,994
Cash and cash equivalents 2,955 2,779
Total current assets 13,417 13,958
Total assets 28,977 31,413
Equity attributable to Parent Company shareholders 8,803 10,774
Non-controlling interests 45 5
Total equity 8,848 10,779
Non-current liabilities
Interest-bearing liabilities
4
6,195 4,807
Lease liabilities 961 1,095
Other non-current liabilities 626 736
Total non-current liabilities 7,781 6,639
Current liabilities
Interest-bearing liabilities
4
178 1,122
Lease liabilities 233 224
Accounts payable 1,837 1,550
Advances from customers 4,067 4,893
Prepaid income 2,831 2,945
Accrued expenses 2,245 2,212
Other current liabilities 957 1,051
Total current liabilities 12,348 13,996
Total equity and liabilities 28,977 31,413

Changes in consolidated equity – condensed

Apr 30
SEK M 2024/25 2023/24
Attributable to Parent Company shareholders
Opening balance 10,774 9,729
Comprehensive income for the period -1,072 1,942
Incentive programs 18 19
Dividend -917 -917
Total 8,803 10,774
Attributable to non-controlling interests
Opening balance 5 4
Comprehensive income for the period 0 1
Acquisition of non-controlling interest 40 -
Total 45 5
Closing balance 8,848 10,779

Consolidated cash flow statement condensed

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
Income after financial items -307 529 490 1,668
Amortization and depreciation 322 299 1,299 1,136
Impairment 1,064 13 1,094 13
Interest net 120 92 382 306
Other non-cash items 164 80 263 247
Interest received and paid -145 -109 -388 -257
Income taxes paid -15 -27 -311 -431
Operating cash flow 1,204 877 2,829 2,681
Change in inventories 302 357 325 -93
Change in operating receivables -197 602 -657 313
Change in operating liabilities 259 -518 128 -441
Change in working capital 364 441 -203 -220
Cash flow from operating activities 1,568 1,317 2,626 2,461
Investments in intangible assets -291 -378 -1,370 -1,392
Investments in tangible assets -28 -67 -200 -254
Continuous investments -320 -445 -1,570 -1,645
Cash flow after continuous investments 1,248 872 1,056 815
Business combinations and investments in other shares 0 - -102 -278
Cash flow after investments 1,248 872 954 538
Dividends -458 -458 -917 -917
Cash flow
from other financing activities
-1,187 -65 310 -182
Cash flow for the period -397 348 347 -562
Change in cash and cash equivalents during the period
Cash and cash equivalents at the beginning of the period 3,583 2,352 2,779 3,278
Cash flow
for the period
-397 348 347 -562
Exchange rate differences -230 79 -170 62
Cash and cash equivalents at the end of the period 2,955 2,779 2,955 2,779

Parent company

Income statement and statement of comprehensive income - condensed

Full year
SEK M 2024/25 2023/24
Operating income and expenses 49 -31
Financial net 561 350
Income after financial items 610 319
Tax -
3
-
4
Net income for the period 607 316
Statement of comprehensive income
Net income for the period 607 316
Total comprehensive income 607 316

Balance sheet - condensed

Apr 30 Apr 30
SEK M 2025 2024
Non-current assets
Intangible assets 14 18
Shares in subsidiaries 4,530 4,829
Receivables from subsidaries 1,676 1,705
Other financial assets 36 29
Deferred tax assets 33 26
Total non-current assets 6,289 6,608
Current assets
Receivables from subsidaries 3,811 3,496
Other current receivables 76 86
Cash and cash equivalents 1,360 1,472
Total current assets 5,247 5,054
Total assets 11,536 11,662
Shareholders' equity 1,685 1,988
Non-current liabilities
Interest-bearing liabilities 6,248 4,807
Provisions 22 16
Total non-current liabilities 6,270 4,823
Current liabilities
Interest-bearing liabilities - 1,000
Liabilities to Group companies 3,462 3,750
Other current liabilities 119 101
Total current liabilities 3,581 4,851
Total shareholders' equity and liabilities 11,536 11,662

Key figures and data per share

Key figures

Full-year May - Apr
2019/20 2020/21 2021/22 2022/23 2023/24 2024/25
17,735 17,411 18,364 20,143 19,697 19,718
14,601 13,763 14,548 16,869 18,119 18,016
42.0 40.8 37.4 37.6 37.4 37.4
42.0 40.8 37.4 38.1 37.5 37.8
1,657 1,906 1,643 1,431 2,039 890
11.3 13.9 11.3 8.5 11.3 4.9
1,657 1,906 1,643 1,743 2,145 2,097
11.3 13.9 11.3 10.3 11.8 11.6
8,113 8,197 8,913 9,729 10,774 8,803
14 16 14 10 13 2
1,632 774 1,532 2,442 3,150 3,477
35 82 69 76 77 80
4,117 4,194 4,631 4,587 4,607 4,536

1 Attributable to Parent Company shareholders.

Data per share

Full-year May - Apr
2019/20 2020/21 2021/22 2022/23 2023/24 2024/25
Earnings per share
before dilution, SEK 2.84 3.28 3.02 2.47 3.41 0.62
after dilution, SEK 2.84 3.28 3.02 2.47 3.41 0.62
Adjusted earnings per share
before dilution, SEK 2.84 3.28 3.02 3.11 3.62 3.08
after dilution, SEK 2.84 3.28 3.02 3.10 3.62 3.08
Cash flow per share
before dilution, SEK -0.74 5.07 0.55 0.91 1.41 2.50
after dilution, SEK -0.74 5.07 0.55 0.91 1.41 2.50
Shareholders' equity per share
before dilution, SEK 21.23 21.45 23.33 25.46 28.20 23.04
after dilution, SEK 21.23 21.45 23.33 25.44 28.20 23.04
Average number of shares
before dilution, thousands 382,062 382,083 382,083 382,083 382,083 382,083
after dilution, thousands 382,062 382,083 382,083 382,367 382,086 382,139
Number of shares at closing 1
before dilution, thousands 382,083 382,083 382,083 382,083 382,083 382,083
after dilution, thousands 382,083 382,083 382,083 382,575 382,086 382,135

1 Number of registered shares at closing excluding treasury shares (1,485,289 per April 30, 2025).

Data per quarter

2022/23 2023/24 2024/25
SEK M Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Gross order intake 6,359 3,839 4,989 4,433 6,436 4,192 4,317 5,418 5,792
Net sales 5,125 3,828 4,732 4,537 5,023 3,825 4,341 4,695 5,156
Operating income (EBIT) 784 412 525 485 617 174 388 525 -197
Cash flow
from operating activities
1,991 -551 623 1,072 1,317 -493 456 1,095 1,568

R&D expenditure

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
R&D expenditure, gross 479 578 2,217 2,224
Capitalization -274 -362 -1,207 -1,331
Amortization 169 137 663 511
Impairment 1,002 - 1,002 -
R&D expenditure, net 1,376 354 2,676 1,404

Note 1 – Accounting principles

This interim report is prepared, with regards to the Group, according to IAS 34 and the Swedish Annual Accounts Act and, with regards to the Parent Company, according to the Swedish Annual Accounts Act and RFR 2. The accounting principles applied are consistent with those presented in Note 1 of the Annual Report 2023/24.

New or revised standards and interpretations, not yet applied, are not considered to have a material impact on the Elekta Group´s financial statements.

All figures are stated in SEK M and, accordingly, rounding differences can occur. Comparisons refer to the corresponding period for the prior year, unless otherwise stated.

Definitions can be found on pages 103-105 in the Annual Report 2023/24.

Related party transactions

Related party transactions are described in note 37 in the Annual Report for 2023/24. The consultancy agreements with two board members that existed in FY 2023/24 have been terminated.

Exchange rates

For Group companies with a functional currency other than Swedish kronor, order intake and income statements are translated at average exchange rates for the reporting period, while balance sheets are translated at closing exchange rates.

Country Currency Average rate Closing rate
Q4 Apr 30
2025 2024 1
Δ
2025 2024 1
Δ
China 1 CNY 1.462 1.478 -1% 1.328 1.513 -12%
Euroland 1 EUR 11.374 11.514 -1% 10.977 11.729 -6%
Great Britain 1 GBP 13.522 13.368 1% 12.924 13.744 -6%
Japan 1 JPY 0.070 0.073 -4% 0.068 0.070 -3%
United States 1 USD 10.560 10.635 -1% 9.651 10.955 -12%

1 April 30, 2025, vs April 30, 2024.

Note 2 – Segment reporting

Elekta applies geographical segmentation. Net sales and contribution margin for the respective regions are reported to Elekta's CFO and CEO (chief operating decision makers). The regions' expenses are directly attributable to the respective regions' reported figures including cost of products sold. Global costs for R&D, marketing, management of product supply centers and Parent Company are not allocated per region. Currency exposure is concentrated to product supply centers. The majority of exchange differences in operations are reported in global costs.

Elekta's operations are characterized by significant quarterly variations in volumes and product mix, which have a direct impact on net sales and profits. This is accentuated when the operation is split into segments, as is the impact of currency fluctuations between the years. In general, revenue from Solutions is recognized at a point in time and revenue from Services are recognized over time.

Q4 2024/25

Other / Group
SEK M Americas EMEA APAC Group-wide total % of net sales
Net sales 1,371 2,014 1,771 - 5,156
Operating expenses -914 -1,210 -1,095 - -3,219 62%
Contribution margin 457 804 676 - 1,937 38%
Contribution margin, % 33% 40% 38%
Global costs - - - -1,094 -1,094 21%
Adjusted EBIT 457 804 676 -1,094 843 16%
Items affecting comparability1 0 -
6
0 -1,034 -1,040
Operating income (EBIT) 457 798 676 -2,128 -197 -4%
Net financial items - - - -109 -109
Income after financial items 457 798 676 -2,237 -307
Income tax - - - -74 -74
Net income for the period 457 798 676 -2,312 -381

Q4 2023/24

Other / Group
SEK M Americas EMEA APAC Group-wide total % of net sales
Net sales 1,526 1,769 1,728 - 5,023
Operating expenses -923 -1,259 -1,184 - -3,366 67%
Contribution margin 604 510 543 - 1,657 33%
Contribution margin, % 40% 29% 31%
Global costs - - - -1,006 -1,006 20%
Adjusted EBIT 604 510 543 -1,006 651 13%
Items affecting comparability1 -
8
-
1
0 -26 -34
Operating income (EBIT) 596 510 543 -1,032 617 12%
Net financial items - - - -88 -88
Income after financial items 596 510 543 -1,120 529
Income tax - - - -115 -115
Net income for the period 596 510 543 -1,235 414

1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost.

Full year 2024/25

Other / Group
SEK M Americas EMEA APAC Group-wide total % of net sales
Net sales 5,183 6,580 6,253 - 18,016
Operating expenses -3,216 -4,247 -4,020 - -11,482 64%
Contribution margin 1,967 2,333 2,233 - 6,534 36%
Contribution margin, % 38% 35% 36%
Global costs - - - -4,437 -4,437 25%
Adjusted EBIT 1,967 2,333 2,233 -4,437 2,097 12%
Items affecting comparability1 -21 -12 -
9
-1,164 -1,207
Operating income (EBIT) 1,946 2,321 2,224 -5,601 890 5%
Net financial items - - - -400 -400
Income after financial items 1,946 2,321 2,224 -6,001 490
Income tax - - - -250 -250
Net income for the period 1,946 2,321 2,224 -6,251 240

Full year 2023/24

Other / Group
SEK M Americas EMEA APAC Group-wide total % of net sales
Net sales 5,436 6,550 6,134 - 18,119
Operating expenses -3,358 -4,527 -4,294 - -12,179 67%
Contribution margin 2,078 2,023 1,840 - 5,940 33%
Contribution margin, % 38% 31% 30%
Global costs - - - -3,795 -3,795 21%
Adjusted EBIT 2,078 2,023 1,840 -3,795 2,145 12%
Items affecting comparability1 -
8
-
9
-
6
-83 -106
Operating income (EBIT) 2,070 2,014 1,834 -3,879 2,039 11%
Net financial items - - - -371 -371
Income after financial items 2,070 2,014 1,834 -4,250 1,668
Income tax - - - -365 -365
Net income for the period 2,070 2,014 1,834 -4,615 1,302

1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost.

Note 3 – Net sales by product type

In general, net sales from Solutions is taken at a point in time, net sales from Service is taken over time.

Q4 2024/25

SEK M Americas EMEA APAC Group total
Solutions 642 1,265 1,279 3,186
Service 729 749 491 1,970
Total 1,371 2,014 1,771 5,156

Q4 2023/24

SEK M Americas EMEA APAC Group total
Solutions 711 1,072 1,277 3,060
Service 815 697 450 1,963
Total 1,526 1,769 1,728 5,023

Full year 2024/25

SEK M Americas EMEA APAC Group total
Solutions 2,181 3,694 4,358 10,232
Service 3,002 2,886 1,896 7,784
Total 5,183 6,580 6,253 18,016

Full year 2023/24

SEK M Americas EMEA APAC Group total
Solutions 2,346 3,883 4,404 10,633
Service 3,090 2,666 1,730 7,487
Total 5,436 6,550 6,134 18,119

Note 4 – Financial instruments

The table below shows the fair value of the Group's financial instruments, for which fair value is different than carrying value. The fair value of all other financial instruments is assumed to correspond to the carrying value.

Apr 30, 2025 Apr 30, 2024
SEK M Carrying
amount
Fair
value
Carrying
amount
Fair
value
Long-term interest-bearing liabilities 6,195 6,505 4,807 5,531
Short-term interest-bearing liabilities 178 178 1,122 1,174

The Group's financial assets and financial liabilities, which have been measured at fair value, have been categorized in the fair value hierarchy. The different levels are defined as follows:

  • Level 1: Quoted prices on an active market for identical assets or liabilities
  • Level 2: Other observable data than quoted prices included in Level 1, either directly (that is, price quotations) or Indirectly (that is, obtained from price quotations)
  • Level 3: Data not based on observable market data

Financial instruments measured at fair value

SEK M Level Apr 30, 2025 Apr 30, 2024
FINANCIAL ASSETS
Financial assets measured at fair value through income statement:
Derivative financial instruments – non-hedge accounting 2 33 42
Short-term investments classified as cash equivalents 1 - -
Derivatives used for hedging purposes:
Derivative financial instruments – hedge accounting 2 174 149
Total financial assets measured at fair value 207 190
FINANCIAL LIABILITIES
Financial liabilities at fair value through income statement:
Derivative financial instruments – non-hedge accounting 2 79 11
Contingent considerations 3 75 76
Derivatives used for hedging purposes:
Derivative financial instruments – hedge accounting 2 51 120
Total financial liabilities measured at fair value 205 207

Movements financial instruments level 3

SEK M Apr 30, 2025 Apr 30, 2024
Opening balance 76 21
Business combinations 48 68
Payments -43 -12
Reported in net income for the period 1 -
Translation differences -6 -2
Closing balance 75 76

The fair value of accounts receivables, other current and non-current receivables, cash and cash equivalents, accounts payable and other current and non-current liabilities is estimated to be equal to their carrying amount.

Note 5 – Intangible assets, Leases and Fixed assets

SEK M Intangible assets Leases Tangible assets Total
Opening Balance, May 1 2024 13,336 1,164 1,062 15,562
Additions 1,534 225 200 1,958
Depreciation -841 -241 -218 -1,299
Impairment -1,013 -38 -43 -1,094
Translation differences -1,116 -72 -83 -1,271
Other items 16 -31 -18 -33
Closing Balance, April 30 2025 11,917 1,006 901 13,823

Alternative performance measures

Alternative Performance Measures (APMs) are measures and key figures that Elekta's management and other stakeholders use when managing and analyzing Elekta's business performance. These measures are not substitutes, but rather supplements to financial reporting measures prepared in accordance with IFRS. Key figures and other APMs used by Elekta are defined on ir.elekta.com/investors/financials. Definitions and additional information on APMs can also be found on pages 103-105 in the Annual Report 2023/24.

Sales growth based on constant exchange rates

Sales growth based on constant exchange are, to a large extent, reported in subsidiaries with other functional currencies than SEK, which is the group reporting currency. In order to present sales growth on a more comparable basis and to show the impact of currency fluctuations, sales growth based on constant exchange rates are presented. The schedule below present growth based on constant exchange rates reconciled to the total growth reported in accordance with IFRS.

Americas EMEA APAC Group total
% SEK M % SEK M % SEK M % SEK M
Q4 2024/25 vs. Q4 2023/24
Change based on constant exchange rates -
6
-94 16 288 5 91 6 286
Currency effects -
4
-62 -
2
-43 -
3
-48 -
3
-153
Reported change -10 -156 14 246 2 43 3 133
Q4 2023/24 vs. Q4 2022/23
Change based on constant exchange rates -
2
-26 -
6
-119 2 29 -
2
-116
Currency effects 1 20 1 28 -
2
-33 0 14
Reported change 0 -
6
-
5
-91 0 -
5
-
2
-102
May - Apr 2024/25 vs. May - Apr 2023/24
Change based on constant exchange rates -
2
-132 1 98 4 224 1 190
Currency effects -
2
-121 -
1
-67 -
2
-105 -
2
-293
Reported change -
5
-253 0 30 2 119 -
1
-103
May - Apr 2023/24 vs. May - Apr 2022/23
Change based on constant exchange rates 1 70 6 357 8 461 5 887
Currency effects 2 128 5 286 -
1
-50 2 363
Reported change 4 197 11 643 7 410 7 1,250

Change of expenses

Management reviews the development of expenses excluding items affecting comparability in constant currencies. The schedule below illustrates the reported change in expenses for items affecting comparability and the remaining change split between change based on constant exchange rates and change due to currency movements.

Administrative
Selling expenses
expenses
R&D expenses
Change expenses
% SEK M % SEK M % SEK M % SEK M
Q4 2024/25 vs. Q4 2023/24
Change in items affecting comparability 5 22 0 -1 274 959 89 980
Change based on constant exchange rates -2 -9 0 1 21 73 6 65
Currency effects -3 -14 -1 -4 -3 -10 -2 -28
Reported change 0 0 -1 -4 292 1,022 92 1,018
Q4 2023/24 vs. Q4 2022/23
Change in items affecting comparability 2 8 5 16 1 4 3 28
Change based on constant exchange rates 5 18 15 45 20 58 12 121
Currency effects -1 -3 -1 -2 0 1 0 -4
Reported change 6 22 19 59 22 63 15 144
May - Apr 2024/25 vs. May - Apr 2023/24
Change in items affecting comparability 1 21 1 18 73 1,013 24 1,052
Change based on constant exchange rates 1 19 1 8 19 268 7 296
Currency effects -2 -31 1 17 -1 -9 -1 -24
Reported change 1 9 3 43 91 1,272 31 1,323
May - Apr 2023/24 vs. May - Apr 2022/23
Change in items affecting comparability 2 29 3 42 1 10 2 82
Change based on constant exchange rates 3 45 0 2 1 16 2 63
Currency effects 1 17 5 60 2 26 2 103
Reported change 6 91 8 104 4 52 6 247

EBITDA

EBITDA is used for the calculation of operational cash conversion and the net debt/EBITDA ratio.

SEK M Q4 2023/24 Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25
Operating income (EBIT) 617 174 388 525 -197
Amortization intangible assets:
Capitalized development costs 139 159 165 179 172
Assets relating to other intangibles 34 39 40 45 41
Depreciation tangible assets 127 119 116 114 109
Impairment 13 31 -
3
3 1,064
EBITDA 930 522 706 866 1,189

Return on shareholders' equity

Return on shareholders' equity measures the return generated on shareholders' capital invested in the company.

SEK M Q4 2023/24 Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25
Net income (12 months rolling) 1,302 1,134 1,002 1,037 237
Average shareholders' equity excluding
non-controlling interests (last five quarters)
10,266 10,460 10,502 10,585 10,297
Return on shareholders' equity 13% 11% 10% 10% 2%

Operational cash conversion

Cash flow is a focus area for management. The operational cash conversion shows the relation between cash flow from operating activities and EBITDA.

SEK M Q4 2023/24 Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25
Cash flow
from operating activities
1,317 -493 456 1,095 1,568
EBITDA 930 522 706 866 1,189
Operational cash conversion 142% -95% 65% 126% 132%

Working capital

In order to optimize cash generation, management focuses on working capital and reducing lead times between orders booked and cash received.

Apr 30 Apr 30
SEK M 2025 2024
Working capital assets
Inventories 2,756 3,259
Accounts receivable 3,625 3,877
Accrued income 2,261 2,050
Other operating receivables 1,308 1,411
Sum working capital assets 9,950 10,596
Working capital liabilities
Accounts payable 1,837 1,550
Advances from customers 4,067 4,893
Prepaid income 2,831 2,945
Accrued expenses 2,245 2,212
Short-term provisions 148 148
Other current liabilities 516 595
Sum working capital liabilities 11,644 12,342
Net working capital -1,694 -1,746
% of rolling 12 months net sales -9% -10%

Net debt and net debt/EBITDA ratio

Net debt is important for understanding the financial stability of the company. Net debt and net debt/EBITDA ratio are used by management to track the debt evolvement, the refinancing need and the leverage for the Group.

SEK M Apr 30, 2024 Jul 31, 2024 Oct 31, 2024 Jan 31, 2025 Apr 30, 2025
Long-term interest-bearing liabilities 4,807 4,811 6,307 6,291 6,195
Short-term interest-bearing liabilities 1,122 1,679 1,747 1,330 178
Derivatives, net - - 0 10 60
Cash and cash equivalents and short-term investments -2,779 -2,364 -3,352 -3,583 -2,955
Net debt 3,150 4,126 4,702 4,047 3,477
EBITDA (12 months rolling) 3,189 3,018 2,925 3,025 3,283
Net debt/EBITDA ratio 0.99 1.37 1.61 1.34 1.06

Items affecting comparability by segment and nature of expense

Items affecting comparability include cost attributable to the Cost-reduction Initiative. The costs are adjusted in order to track the underlying profitability of the Group's products and services.

Q4 2024/25

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Items affecting comparability:
Personnel related cost 0 6 0 3 9
Depreciation and impairment - - 0 1,064 1,064
Other cost - 0 0 -33 -33
Total 0 6 0 1,034 1,040

Q4 2023/24

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Items affecting comparability:
Personnel related cost 8 0 -0 15 23
Depreciation and impairment - 0 - 7 8
Other cost - 0 - 3 4
Total 8 1 0 26 34

Full year 2024/25

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Items affecting comparability:
Personnel related cost 21 12 9 88 130
Depreciation and impairment - - - 1,094 1,094
Other cost 0 0 0 -17 -17
Total 21 12 9 1,164 1,207

Full year 2023/24

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Items affecting comparability:
Personnel related cost 8 7 6 58 80
Depreciation and impairment - 0 - 8 8
Other cost - 1 - 18 19
Total 8 9 6 83 106

Gross margin & Adjusted gross margin

Gross margin is used to track operational performance and efficiency and Adjusted gross margin is used to track the underlying operational performance, i.e. excluding items affecting comparability.

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
Net sales 5,156 5,023 18,016 18,119
Cost of products sold -3,102 -3,194 -11,270 -11,342
Gross income 2,053 1,829 6,746 6,777
Items affecting comparability 22 7 64 26
Adjusted gross income 2,075 1,837 6,810 6,803
Gross margin (Gross income/ Net sales) 39.8% 36.4% 37.4% 37.4%
Adjusted gross margin (Adjusted gross income/ Net sales) 40.3% 36.6% 37.8% 37.5%

EBITDA-margin & Adjusted EBITDA-margin

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
EBITDA 1,189 930 3,283 3,189
Items affecting comparability -24 27 113 98
Adjusted EBITDA 1,165 956 3,396 3,287
Net Sales 5,156 5,023 18,016 18,119
EBITDA-margin (EBITDA/Net sales) 23.1% 18.5% 18.2% 17.6%
Adjusted EBITDA-margin (Adjusted EBITDA/Net sales) 22.6% 19.0% 18.8% 18.1%

Adjusted EBIT by segment

Adjusted EBIT is used to track the underlying operational performance, i.e. excluding items affecting comparability.

Q4 2024/25

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Operating Income (EBIT) 457 798 676 -2,128 -197
Items affecting comparability - 6 0 1,034 1,040
Adjusted EBIT 457 804 676 -1,094 843
Q4 2023/24
SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Operating Income (EBIT) 596 510 543 -1,032 617
Items affecting comparability 8 1 0 26 34
Adjusted EBIT 604 510 543 -1,006 651

Full year 2024/25

SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Operating Income (EBIT) 1,946 2,321 2,224 -5,601 890
Items affecting comparability 21 12 9 1,164 1,207
Adjusted EBIT 1,967 2,333 2,233 -4,437 2,097
Full year 2023/24
SEK M Americas EMEA APAC Other /
Group-wide
Group
total
Operating Income (EBIT) 2,070 2,014 1,834 -3,879 2,039
Items affecting comparability 8 9 6 83 106
Adjusted EBIT 2,078 2,023 1,840 -3,795 2,145

Adjusted earnings per share

Adjusted earnings per share is used to track the underlying operational performance, i.e. excluding items affecting comparability.

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
Net income for the period attributable to:
Parent Company shareholders -386 415 237 1,302
Items affecting comparability 1,040 34 1,207 106
Tax on Items affecting comparability -229 -
8
-266 -24
Adjusted net income 425 441 1,178 1,384
Average number of shares, before dilution 382 382 382 382
Average number of shares, after dilution 382 382 382 382
Adjusted earnings per share before dilution 1) 1.11 1.15 3.08 3.62
Adjusted earnings per share after dilution 2) 1.11 1.15 3.08 3.62

1) Adjusted net income/average number of shares before dilution 2) Adjusted net income/average number of shares after dilution

Adjusted R&D expenditure of net sales

Adjusted R&D expenditure of net sales is used to track the amount spent on R&D in relation to net sales during the period, excluding items affecting comparability.

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
R&D expenditure, net 1,376 354 2,676 1,404
R&D items affecting comparability -962 -
4
-1,023 -10
R&D capitalization 274 362 1,207 1,331
R&D amortization -169 -137 -663 -511
Adjusted R&D Expenditure, gross 519 575 2,197 2,214
Net Sales 5,156 5,023 18,016 18,119
Adjusted R&D Expenditure of net sales 10% 11% 12% 12%

Book-to-bill

Book-to-bill is used to measure the company's growth. A quota exceeding 1 shows that gross order intake is higher than the net sales.

Q4 Full year
SEK M 2024/25 2023/24 2024/25 2023/24
Gross order intake 5,792 6,436 19,718 19,697
Net sales 5,156 5,023 18,016 18,119
Book-to-bill 1.12 1.28 1.09 1.09

About Elekta

Elekta is a global leader in radiotherapy solutions to fight cancer and neurological diseases. In fact, we are the only independent radiotherapy provider of scale. We have a broad offering of advanced solutions for delivering the most efficient radiotherapy treatments. Elekta's offering allows clinicians to treat more patients with increased quality, both with valuecreating innovations in solutions and AI-supported service based on a global network.

Elekta AB Box 7593 SE – 103 93 Stockholm, Sweden T +46 8 587 254 00 F +46 8 587 255 00

elekta.com /elekta @elekta /company/elekta @elekta_

Talk to a Data Expert

Have a question? We'll get back to you promptly.